What is degarelix power used for?

Degarelix powder is a man-made decapeptide that works as a selective GnRH (gonadotropin-releasing hormone) receptor blocker. It is mostly used in drug research and development for advanced prostate cancer treatments. This substance blocks pituitary GnRH receptors right away and for a long time, while other hormone modulators take weeks to reach a level of testosterone reduction equivalent to castration. The chemical name for degarelix acetate is 214766-78-6, and its molecular weight is 1632.26 g/mol. It is a good choice for research and development teams that want to do quick androgen restriction studies without the side effects that come with agonist-based treatments. It comes in the form of a white, lyophilized powder that is stable and easy to dose accurately, which is very important in controlled laboratory settings.

Understanding Degarelix Powder and Its Primary Uses

Chemical Composition and Structural Attributes

Degarelix acetate has a special sequence of amino acids called Ac-D-Nal-D-Cys-D-Phe-D-Trp-Lys-D-Ala-Leu-Lys-Pro-D-Ala-NH₂. This sequence has several D-amino acid changes that make it more resistant to being broken down by proteases. Its peptidic complexity is shown by the chemical formula C₈₂H₁₀₃ClN₁₈O₁₆. Custom synthesis is needed for supply lines to be dependable. This substance meets the high quality standards of pharmaceutical firms because its purity levels are always kept at ≥98.0% through HPLC analysis. The acetate salt form dissolves well in both water and acidic buffers, which makes recovery easier in labs where exact molarity is important for repeatability.

Core Applications in Oncology Research

Androgen-deprivation therapy processes are studied in prostate cancer study labs with degarelix. The substance is used as a standard in pharmacokinetic studies so that scientists can model how testosterone suppression works without having to use animal models that are more variable with slower-acting options. Medical research groups that are looking into combination treatment protocols—that is, using new checkpoint inhibitors along with androgen blockade—need gram-scale amounts of research-grade peptides. Because it has a rapid reduction profile, it is essential for studies looking at how acute hormonal flux affects tumor microenvironments, especially in the development of castration-resistant phenotypes.

Emerging Research Directions

Besides cancer, hormonal research teams are also looking into degarelix's potential to help manage hormone-dependent diseases where quick suppression can be helpful for treatment. To make next-generation GnRH inhibitors with longer half-lives or better tissue selectivity, peptide drug research programs look at its structural patterns. Contract research groups that do preclinical studies that allow for INDs keep high-purity batches on hand to meet the standards for regulatory submissions. The molecule is also used in the development of biochemical assays, where it acts as a positive control in studies of receptor binding, proving that screening tools for new hormone modulators work.

Degarelix Powder Mechanism of Action and Clinical Benefits

Pharmacological Blockade Pathway

Degarelix powder binds very strongly to pituitary GnRH receptors, stopping natural GnRH from starting the luteinizing hormone cycle. This direct antagonistic effect lowers testosterone levels so low that they are below the levels needed for castration within 72 hours. This pharmacodynamic benefit was measured in phase III studies. Agonists stop the testosterone increase that can make bone pain or spinal cord pressing worse in metastatic cases. This is different from agonists, which overstimulate the hypothalamic-pituitary-gonadal axis at first before desensitization. Labs can use research-grade materials to study these receptor rates in vitro, using cell lines that produce recombinant GnRH receptors to find the IC50 values and dissociation constants that are needed for SAR (structure-activity relationship) analysis.

Clinical Efficacy Metrics Relevant to R&D

Studies show that testosterone levels below 0.5 ng/mL stay low throughout treatment cycles. This is a standard that pharmaceutical formulators use to plan dosing schedules for generic development processes. The fast start of the peptide meets the needs of sourcing teams for compounds with well-documented efficacy data to back up regulatory files. Risk-benefit analyses are necessary for designing clinical trials. Safety profiles with doable injection site responses and cardiovascular event rates similar to surgical castration provide the data needed for these analyses. Procurement managers who are looking at API candidates put these factors that are backed up by proof at the top of their list when choosing peptides for long-term supply deals. This is because post-market surveillance data gives formulators more faith in when products will be available for sale.

Dosing Considerations for Research Protocols

For standard clinical protocols, the first dose is 240 mg subcutaneously, and then there are monthly maintenance shots of 80 mg. For preclinical models, research labs scale down these dosing patterns. Understanding these therapeutic levels for humans helps formulation scientists figure out the right amounts for studies on animal efficacy or tissue tests that don't involve living animals. The compound's ability to dissolve in water makes recovery easier, but researchers need to be aware of the risk of peptide aggregation in neutral pH settings. Lyophilized material stored at -20°C keeps its potency for up to 24 months, which fits with the timelines of R&D projects that need regular amounts of material.

Comparing Degarelix Powder with Alternative Therapies

Efficacy Benchmarking Against GnRH Agonists

Established GnRH agonists, leuprolide and goserelin, are used in most traditional prostate cancer treatments. However, they cause a 7–14 day testosterone flare-up that needs to be treated with an androgen blocker at the same time. By blocking receptors right away, Degarelix gets rid of this problem, making procedure designs for clinical trials simpler. When procurement experts look at treatment portfolios, they notice that agonists have depot formulations with longer dosing intervals, but antagonists' consistent pharmacokinetics make patient stratification easier in studies that need tight hormonal control. When looking at cost-per-treatment, agonists are more popular in price-sensitive markets. However, the therapeutic difference makes it worth charging more for goods that are aimed at advanced-stage patients where preventing flare-ups is very important.

Therapeutic Niche in Combination Strategies

More and more study in oncology is looking at degarelix as part of multimodal treatments that combine radiation therapy or next-generation antiandrogens like enzalutamide with rapid androgen reduction. The compound's clean mechanism—it doesn't have any off-target steroidogenic effects—makes it a great way to test how different drugs interact with each other. Generic drug makers and CRO partners need reference standards that show compatibility with a wide range of therapeutic agents. This increases the need for impurity-controlled amounts where residual synthesis byproducts won't mess up combination pharmacology studies. This makes high-purity peptide sources very important for translational research, which takes findings made in the lab and applies them to patients.

Market Positioning for Procurement Teams

Pharmaceutical trade businesses that are looking to add new drugs to their portfolios should look at Degarelix powder's patents and the time it takes to be exclusive in the market. For biosimilar development paths for complex peptides to work, suppliers must be able to deliver multigram amounts that are consistent from batch to batch, which can be checked using different chemical methods. Regulatory reports need a lot of paperwork, like forced degradation studies, impurity tracking, and peptide mapping. Manufacturers who are already ISO and GMP certified are more likely to be able to handle this. When procurement managers weigh cost against compliance, they know that professional help from suppliers, such as advice on how to handle, store, and validate products, often outweighs small price differences when it comes to choosing long-term partners.

Procurement Guide: Sourcing Degarelix Powder for B2B Buyers

Supplier Qualification Criteria

Checking for GMP compliance through site audit records or third-party certifications is the first step in finding trustworthy manufacturers. Suppliers should give Drug Master Files (DMF) paperwork that works with FDA or EMA entries. This shows that the process has been checked and the quality system is mature. Customer comments from well-known pharmaceutical companies or contract research organizations (CROs) show that the business is reliable, and membership in industry groups like IPEC shows that the business follows the standards for excipients that apply to peptide APIs. By asking for sample batches along with Certificates of Analysis, procurement teams can make sure that the claimed standards are met through independent testing. This includes making sure that the HPLC is pure, that the amino acid analysis shows the correct amount of peptides, and that the leftover solvent levels follow ICH Q3C guidelines.

Negotiating Bulk Orders and Pricing Models

Early-stage research needs minimum order quantities starting at 1 gram, but pharmaceutical-scale projects need kilogram quantities, which means they need custom synthesis rates. Most tiered pricing systems offer price drops at 100-gram and 1-kilogram levels, but procurement managers should weigh the pledge to buy in bulk against the assurance of a steady supply of goods. Payment terms that balance letter-of-credit protection with the supplier's limited cash flow make foreign business easier, especially when working with manufacturers in developing markets that offer low prices. Long-term contracts that call for orders every three months keep budgets stable and give sellers more information about how to plan their production, which often leads to better prices that can't be gotten through spot purchases.

Logistics and Storage Best Practices

Because degarelix acetate absorbs water, it needs to be packed in double-sealed aluminum foil bags inside fiberboard drums with desiccant packs to keep the moisture out. International shipping using cold-chain operations keeps the storage temperature at -20°C while it's in transit. However, short-term temperature changes of up to 25°C for 48 hours are still fine according to stability data. Documents for customs must correctly list the compound under HTS code 2937.90 (polypeptide hormones), and they must be supported by COAs and usage statements that say "research purposes only" to speed up the clearing process. When planning cross-border supplies, procurement teams should hire freight forwarders with experience in pharmaceutical shipping. This will make sure that all import permits needed by places like the EU or Japan are met.

Ensuring Quality and Compliance in Degarelix Powder Acquisition

Critical Quality Attributes to Verify

Certificates of Analysis for Degarelix powder must show the amount of peptides present by using quantitative amino acid analysis and giving results that are within 95–105% of the theoretical composition. The main peak of an HPLC chromatogram should show purity levels above 98%, and each impurity peak should be less than 0.5%. This is especially important for checking for des-amino breakdown products. Trifluoroacetic acid left over from reverse-phase purification is a typical byproduct of synthesis that needs to stay below 0.1% to keep the mixture from becoming unstable. Endotoxin levels below 5 EU/mg and the lack of microbial contamination confirmed by sterility tests are in line with ICH Q6B standards for biotechnology-derived goods, even though degarelix comes from solid-phase synthesis instead of fermentation.

Regulatory Documentation Expectations

Pharmaceutical buying requires full regulatory support packages that include models of the manufacturing process, lists of starting materials, and rules for retesting and expiration dates. For customers to make sure their methods are correct, suppliers should give them reference standards that can be calibrated to NIST standards. They should also give customers data on how stable the standards are under heat, light, and reactive stress. For EU imports, REACH pre-registration proof is necessary. For other countries, like Korea or Japan, TCCA or PMDA notices may be needed. Quality agreements that make change control procedures official make sure that suppliers tell buyers about any changes to the manufacturing site or processes that might affect how well two products compare. This keeps buyers safe from unexpected batch failures that could delay trial timelines.

Building Resilient Supply Chains

By having a variety of suppliers in different areas, you lower your risk of being affected by changes in regional laws or political unrest. Qualifying secondary sources through shortened development programs that use current analytical methods speeds up the launching of backup suppliers when primary sources run into capacity issues. Keeping a 6-month safety stock in your inventory management strategy helps you balance the costs of keeping stock with the risks of lead times, especially for peptides that need 8–12 week custom synthesis cycles. By sharing the progress of the pipeline and expected scale-up needs with suppliers during collaborative forecasting, it is possible to allocate capacity in a way that ensures continuous material supply throughout the clinical development phases.

Conclusion

Degarelix powder is a unique but strategically important peptide for drug research and development that focuses on hormone-dependent disease processes. Because it quickly blocks GnRH, it has many benefits over other treatments, which makes it very useful for studying prostate cancer, endocrine systems, and making new peptide drugs. For buying to go well, providers must have strong quality systems, know how to deal with regulations, and have the technical know-how to support complex peptide manufacturing. As research into biosimilars and combination therapies grows, so will the need for high-purity, well-characterized degarelix batches. Purchasing teams that build solid supply relationships early on will be rewarded.

FAQ

What purity level is required for pharmaceutical research applications?

Research-grade degarelix should always show that it is at least 98% pure by HPLC and have a peptide content of 95% to 105% by quantitative amino acid analysis. For early screening tests, lower purity grades might be enough, but for regulatory research work, you need pharmaceutical-grade material that meets standard requirements. Asking for batch-specific impurity profiles helps figure out if any leftover synthesis reagents or breakdown products might mess up certain testing methods.

How does storage temperature affect peptide stability?

Lyophilized degarelix stays active for 24 months when kept at -20°C and dried out. Reconstituted solutions are less stable and usually need to be used within 24 hours or stabilized with the right excipients. Suppliers should do stable studies that show how things break down in different situations. This way, customers can set up storage rules that work with their lab's processes.

Can degarelix be sourced for commercial pharmaceutical manufacturing?

The current product specs say that it can only be used for study, so it can only be used in laboratories and not for making therapeutic products. Pharmaceutical firms that want to go into commercial development must work with suppliers that can scale up synthesis to GMP manufacturing standards and provide all the regulatory paperwork needed to support IND or NDA files. For this shift to happen, suppliers need to be qualified in a lot of ways that go beyond research-grade buying standards.

Partner with Xi'an Yihui for Reliable Degarelix Powder Supply

You can trust Xi'an Yihui Bio-technology Co., Ltd. to make Degarelix powder. They offer pharmaceutical-grade peptides and have 13 years of experience in API and fine chemicals. We offer degarelix acetate that is ≥98% pure according to strict HPLC standards and comes with full COA paperwork. It can be bought in 1g, 100g, or 1kg packages, depending on the size of your study. With ISO, Halal, and Kosher certifications and instant access, we get rid of supply chain uncertainties that cause important R&D deadlines to slip. Our expert team is available 24 hours a day, seven days a week to help customers.

They can walk you through storage methods, reconstitution processes, and the legal paperwork that is needed to buy peptides. As a provider of Degarelix powder to more than 100 countries, we know what pharmaceutical companies, CROs, and research institutions in the US and Europe need in terms of compliance. Get in touch with sales@yihuipharm.com right away to get batch-specific analytical data, talk about custom synthesis options for linked peptide analogs, or get the best deals on large orders.  

References

1. Klotz, L., Boccon-Gibod, L., Shore, N. D., et al. (2008). The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International, 102(11), 1531-1538.

2. Anderson, J., Al-Ali, G., Wirth, M., et al. (2010). Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: Results from a phase IIIb study. Urologic Oncology: Seminars and Original Investigations, 28(2), 182-190.

3. Crawford, E. D., Tombal, B., Miller, K., et al. (2011). A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. Journal of Urology, 186(3), 889-897.

4. Mason, M., Maldonado Pijoan, X., Steidle, C., et al. (2012). Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer. BJU International, 110(11), 1665-1671.

5. Shore, N. D., Abrahamsson, P. A., Anderson, J., et al. (2014). New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer and Prostatic Diseases, 16(1), 7-15.

6. Garnick, M. B., Campion, M., & Abrams, P. (2013). Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncology, 9(1), 87-101.